证券代码：688506 证券简称：百利天恒 公告编号：2025-044 四川百利天恒药业股份有限公司 2025 年 5 月 31 日 关于向特定对象发行股票申请文件的审核问询函回复的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）于 2025 年 4 月 30 日收 到上海证券交易所（以下简称"上交所"）出具的《关于四川百利天恒药业股份有 限公司向特定对象发行股票申请文件的审核问询函》（上证科审（再融资）〔2025〕 47 号）（以下简称"《审核问询函》"），上交所审核机构对公司向特定对象发行股 票申请文件进行了审核，并形成了问询问题。 公司收到《审核问询函》后，按照要求会同相关中介机构就《审核问询函》提 出的问题进行了认真研究和逐项落实，根据相关要求对《审核问询函》有关问题进 行了说明和论证，具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn） 披露的《关于四川百利天恒药业股份有限公司 2025 年度向特定对象发行 A 股股票申 请文件的审 ...

全体监事对本次监事会会议议案进行了审议，经表决形成如下决议： 1、审议通过《关于调整公司 2025 年度向特定对象发行 A 股股票方案之募集 资金规模的议案》 证券代码：688506 证券简称：百利天恒 公告编号：2025-040 四川百利天恒药业股份有限公司 第四届监事会第二十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 2025 年 5 月 30 日，四川百利天恒药业股份有限公司第四届监事会第二十次会 议（以下简称"本次会议"）在公司会议室召开。本次会议以现场及通讯表决方式 召开，应出席监事 3 名，实际出席监事 3 名，会议由监事会主席汪捷女士主持。 本次会议的通知于 2025 年 5 月 29 日通过专人、书面等形式送达全体监事，全体 监事一致同意豁免本次会议的提前通知期限要求。本次会议的召集和召开程序符 合《中华人民共和国公司法》（以下简称《公司法》）和《四川百利天恒药业股份 有限公司章程》（以下简称《公司章程》）的规定，会议决议合法、有效。 二、监事会会议审议情况 监事 ...

证券代码：688506 证券简称：百利天恒 公告编号：2025-039 四川百利天恒药业股份有限公司 第四届董事会第二十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 四川百利天恒药业股份有限公司（以下简称"公司"）第四届董事会第二十 二次会议（以下简称"本次会议"）于 2025 年 5 月 30 日在公司会议室召开。本 次会议以现场及通讯表决方式召开，应出席董事 10 名，实际出席董事 10 名，会 议由董事长朱义先生主持。本次会议的通知于 2025 年 5 月 29 日通过专人、书面 等形式送达全体董事，全体董事一致同意豁免本次会议的提前通知期限要求。本 次会议的召集和召开程序符合《中华人民共和国公司法》（以下简称《公司法》） 和《四川百利天恒药业股份有限公司章程》（以下简称《公司章程》）的规定，会 议决议合法、有效。 二、董事会会议审议情况 本次会议按照《公司法》和《公司章程》的有关规定，对以下议案进行审议， 经表决，会议决议如下： 表决结果：同意 10 票；反对 0 票；弃 ...

百利天恒公告，公司自主研发的创新生物药注射用BL-M07D1(HER2ADC)单药用于HER2低表达复发或 转移性乳腺癌的III期临床试验已于近日完成首例受试者入组。BL-M07D1是一种靶向HER2的创新型 ADC，具有同类最佳潜力，已在临床试验中展示出显著的抗肿瘤功效。目前，BL-M07D1正在国内外开 展12项临床试验，覆盖二线及以上HER2阳性乳腺癌、HER2阳性乳腺癌术后辅助、HER2阳性乳腺癌新 辅助治疗和HER2低表达乳腺癌，以及肺癌、消化道肿瘤、泌尿系统肿瘤和妇科肿瘤等多项适应症。 ...

百利天恒(688506.SH)公告称，公司计划向特定对象发行A股股票并募集资金不超过37.64亿元，扣除发 行费用后，实际募集资金将全部用于 创新药研发项目。 ...

Core Viewpoint - The report highlights the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A, indicating a recent decline in net value but strong returns over various time frames [1]. Fund Performance - The latest net value of the fund is 1.5670 yuan, reflecting a decrease of 1.94% - Over the past month, the fund achieved a return of 3.91%, ranking 171 out of 1959 in its category - In the last three months, the fund's return was 22.33%, ranking 5 out of 1950 - Year-to-date, the fund has returned 30.15%, ranking 17 out of 1943 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 64.17%, with the following allocations: - Heng Rui Medicine: 10.23% - Kelun Pharmaceutical: 9.09% - Baile Tianheng: 8.94% - Haizike: 8.27% - Xinlitai: 6.66% - Zai Jian Pharmaceutical-U: 6.10% - Xin Nuo Wei: 4.69% - Rongchang Biotechnology: 3.49% - Nuocheng Jianhua-U: 3.35% - Microelectrophysiology: 3.35% [1]. Fund Background - The Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A was established on June 18, 2015, and as of March 31, 2025, it has a total scale of 4.408 billion yuan - The fund manager is Zhang Wei, who has extensive experience in the pharmaceutical sector [1][2].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The A-share pharmaceutical index has increased by 1.8% this week and 4.3% year-to-date, outperforming the CSI 300 by 1.9% and 5.6% respectively [3][8] - The H-share biotechnology index has seen a rise of 6.7% this week and 36.4% year-to-date, outperforming the Hang Seng Technology Index by -7.4% and 19% [3][8] - The report highlights a significant increase in the number of domestic innovative drugs presented at the ASCO conference, with 25 oral presentations and 24 rapid oral presentations, marking a new high [14] Summary by Sections Industry Performance - A-share raw materials (+4.0%), chemical drugs (+3.6%), biological products (+1.7%), medical services (+1.4%), and pharmaceutical commerce (+1.2%) have shown notable price increases, while medical devices (+0.5%) and traditional Chinese medicine (+0.2%) have seen smaller gains [3][8] - Top performers in A-shares include Shengguojian (+100%), Haichen Pharmaceutical (+52%), and Shutaishen (+49%), while New Ganjing (-12%), Gongdong Medical (-10%), and Jinhao Medical (-9%) faced declines [3][8] R&D Progress and Corporate Developments - GSK's IL-5 monoclonal antibody has been approved for the treatment of COPD, marking a significant milestone as the first IL-5 drug approved for this indication [3] - The report notes strategic partnerships, such as Jingyin Pharmaceutical's collaboration with CRISPR Therapeutics to develop next-generation long-acting FXI-targeting siRNA therapies [3] Investment Strategy - Recommended sub-industry rankings are: Innovative drugs > CXO > Traditional Chinese medicine > Medical devices > Pharmacies > Pharmaceutical commerce [9] - Stock selection strategies include focusing on growth in innovative drugs, undervalued stocks in traditional Chinese medicine, high dividend stocks in traditional Chinese medicine, and left-side opportunities in raw materials and certain CXO and medical devices [9]

Group 1 - The "China Listed Companies Value 100" list for 2024 highlights the importance of advanced manufacturing and AI innovation, high-quality development of private enterprises, and the cultivation of new consumption [1][2] - Yunnan Aluminum Co., Ltd. topped the list with a comprehensive score of 91.59, followed by Huayi Group, Beixin Building Materials, and COSCO Shipping Holdings [1] - The manufacturing sector leads with 67 listed companies, particularly in high-growth areas such as new energy, semiconductors, AI hardware, electronic manufacturing, and innovative pharmaceuticals [1] Group 2 - High-end liquor companies like Kweichow Moutai, Wuliangye, and Shanxi Fenjiu continue to rank on the list, while food and beverage companies like Haitian Flavoring and Dongpeng Special Drink achieve rapid growth through expanded sales channels [2] - The AI industry in China is projected to reach a scale of 269.7 billion yuan in 2024, with a compound annual growth rate of over 30% expected from 2025 to 2029 [2] - The "Data Asset Listed Companies Analysis Report" indicates that 100 companies disclosed data resource entries in their 2024 annual reports, with positive impacts on stock prices concentrated in high-relevance sectors like information technology [3]

Investment Rating - The report assigns a "Buy-A" investment rating to the company with a 12-month target price of 399.56 CNY [4][7]. Core Views - The report highlights the potential of the company's EGFR×HER3 bispecific antibody ADC in the overseas market, especially due to its collaboration with BMS, which is expected to drive significant sales growth [1][2]. - The company has established a strong pipeline in ADC and bispecific antibody fields, with multiple innovative products entering clinical stages, indicating promising future developments [1][3]. Summary by Sections Company Overview - The company is positioned as an innovative drug development enterprise with a global perspective, focusing on ADC and bispecific antibody platforms. It has 15 candidate drugs in clinical stages and over 80 clinical trials globally [12]. Core Product - The core product, BL-B01D1, is the world's first EGFR×HER3 bispecific antibody ADC, currently in collaboration with BMS. The product has shown excellent clinical data and is in advanced clinical trials both domestically and internationally [2][3]. ADC Pipeline - The company has eight ADC drugs in clinical development, including BL-M07D1, which is in phase 3 trials. New generation linker-payload drugs BL-B16D1 and BL-M17D1 have also entered clinical stages [3][21]. Financial Projections - Revenue is expected to improve significantly from 2024 onwards, primarily due to the collaboration with BMS, which includes an upfront payment of 800 million USD and potential milestone payments [21][31]. - The company has faced losses in recent years due to heavy investments in R&D, but profitability is anticipated to improve as core products progress towards commercialization [21][22]. R&D Investment - R&D expenses have increased significantly, reaching 744 million CNY in 2023, with a projected 1.443 billion CNY in 2024, reflecting the company's commitment to advancing its clinical pipeline [27][28]. Management Team - The management team comprises experienced professionals from various fields, providing strong leadership and expertise in drug development and commercialization [15][16]. Market Position - The company has a concentrated ownership structure, with the top ten shareholders holding 88.36% of the shares, indicating strong control by core stakeholders [18][19]. Clinical Development Strategy - The company is actively pursuing overseas development through collaborations with multinational corporations and its subsidiary SystImmune, enhancing its global reach [31][32].

Group 1: MSCI Index Adjustments - MSCI announced the quarterly index adjustments for May 2025, adding 30 stocks and removing 61 stocks from the global equity index (ACWI) [1] - The MSCI China Index included six new stocks, such as Chipone Technology and Baillie Gifford, while removing 17 stocks, including Hisense Home Appliances and Shanghai Pharmaceuticals [1] - The adjustments will take effect after the market closes on May 30 [3] Group 2: Company Performance and Reactions - Baillie Gifford reported a significant decline in Q1 2025 revenue, down 98.77% year-on-year to 67.44 million yuan, with a net loss of 531 million yuan, a 110.62% decrease [1] - The decline in Baillie Gifford's performance was attributed to the absence of large intellectual property licensing income that was recognized in the same period last year [1] - Haikang's representatives stated that their inclusion in the MSCI China Index is more of a market behavior and does not directly correlate with company operations [2] Group 3: Market Sentiment and Future Outlook - Analysts suggest that stocks newly included in the MSCI China Index may experience increased buying from passive index funds, which could positively impact stock price valuation and liquidity [3] - External investors are optimistic about A-share investment opportunities, with over 80% of participants in a recent Morgan Stanley conference indicating a likelihood of increasing exposure to Chinese stocks [5] - The MSCI indices are adjusted quarterly based on objective quantitative metrics such as market capitalization and liquidity [3]